Výsledky vyhledávání - "A. Røssevold"

Akademický článek

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

Autor: J. A. Kyte, A. Røssevold, R. S. Falk, B. Naume

Publikováno v: Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-7 (2020)

Abstract Background Immunotherapy with checkpoint inhibitors (CI) represents an important novel development in cancer treatment. Metastatic triple-negative breast cancer (mTNBC) is incurable, with a median survival of only ~ 13 months. We have initia

Externí odkaz: https://doaj.org/article/574af2ddfba645f7aacd26ef93c5fb2b

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation

Autor: Sudhir Kumar Chauhan, Claire Dunn, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Gjertrud Skorstad, Adam Sike, Bjørnar Gilje, Sunil Xavier Raj, Kanutte Huse, Bjørn Naume, Jon Amund Kyte

Publikováno v: npj Breast Cancer, Vol 10, Iss 1, Pp 1-17 (2024)

Abstract Immunotherapies blocking the PD-1/PD-L1 checkpoint show some efficacy in metastatic breast cancer (mBC) but are often hindered by immunosuppressive mechanisms. Understanding these mechanisms is crucial for personalized treatments, with perip

Externí odkaz: https://doaj.org/article/21138a5be7fa4ef6868ac4e8d5f2a5bf

Zobrazit plný text záznamu

Akademický článek

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial

Autor: Ragnhild Sørum Falk, Bjornar Gilje, Andrea Gombos, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Beate Boge, Randi R. Mathiesen, Lars Julsrud, Øystein Garred, Hege G. Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)

Background Immune checkpoint inhibitors have shown minimal clinical activity in hormone receptor-positive metastatic breast cancer (HR+mBC). Doxorubicin and low-dose cyclophosphamide are reported to induce immune responses and counter regulatory T ce

Externí odkaz: https://doaj.org/article/e9ba64ad31414caeaea3d72626619d91

Zobrazit plný text záznamu